BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement

Reuters

Nov 05, 2025

** Tryptamine Therapeutic TYP.AX falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27

** Biotechnology co to raise A$6.1 million (~$4 million) at A$0.034/share

** Issue price represents 10.5% discount to last close on October 31, when trading was halted pending capital raise

** Stock sees busiest session since October 2024, with ~15.6 mln shares traded - 6.6x the 30-day average

** YTD, TYP falls 2.6%

($1 = A$1.5389)

(Reporting by Jasmeen Ara Shaikh in Bengaluru)

((Jasmeenaraislam.shaikh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581718333"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581718333\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581718333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581718333","market":"us","top_or_hot":-1,"title":"BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement</title></head><body><p>** Tryptamine Therapeutic <span>TYP.AX</span> falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27</p><p>** Biotechnology co to raise A$6.1 million (~$4 million) at A$0.034/share</p><p>** Issue price represents 10.5% discount to last close on October 31, when trading was halted pending capital raise</p><p>** Stock sees busiest session since October 2024, with ~15.6 mln shares traded - 6.6x the 30-day average</p><p>** YTD, TYP falls 2.6%</p><p>($1 = A$1.5389)</p><p> (Reporting by Jasmeen Ara Shaikh in Bengaluru)</p><p> ((Jasmeenaraislam.shaikh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Tryptamine Therapeutic falls on discounted placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 10:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement</title></head><body><p>** Tryptamine Therapeutic <span>TYP.AX</span> falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27</p><p>** Biotechnology co to raise A$6.1 million (~$4 million) at A$0.034/share</p><p>** Issue price represents 10.5% discount to last close on October 31, when trading was halted pending capital raise</p><p>** Stock sees busiest session since October 2024, with ~15.6 mln shares traded - 6.6x the 30-day average</p><p>** YTD, TYP falls 2.6%</p><p>($1 = A$1.5389)</p><p> (Reporting by Jasmeen Ara Shaikh in Bengaluru)</p><p> ((Jasmeenaraislam.shaikh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL6N3WH03T:1","article_id":"2581718333","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581718333","pubTimestamp":1762309163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement** Tryptamine Therapeutic TYP.AX falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27** Biotechnology","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药"},"translate_title":"BUZZ-澳大利亚色胺治疗剂因配售折扣而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYP.AU":0.9},"content_text":"BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement** Tryptamine Therapeutic TYP.AX falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27** Biotechnology co to raise A$6.1 million (~$4 million) at A$0.034/share** Issue price represents 10.5% discount to last close on October 31, when trading was halted pending capital raise** Stock sees busiest session since October 2024, with ~15.6 mln shares traded - 6.6x the 30-day average** YTD, TYP falls 2.6%($1 = A$1.5389) (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((Jasmeenaraislam.shaikh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}